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Introduction
Cervical cancer is the fourth most common cancer 
among women. Median age of diagnosis is about 52 
years, but has a bimodal distribution with picks at 35 to 
39 and 60 to 64 years of age. Annually 500000 death is 
caused by cervical cancer all around the world. In Europe, 
a total of 58,373 new cases of cervical cancer and 24,385 
deaths were reported in 2012. The overall incidence rate 
of cervical cancer in Europe is 10.6 per 100,000 (Jemal 
et al., 2011; Kesic et al., 2012; Ghojazadeh et al., 2013).
Surgery, chemotherapy and radiotherapy are the main 
treatment methods where mostly are used in association 
with other methods for cervical cancer. However, the 
long term prognosis of cervical cancer is still poor, with 
expected 5-year survival rate less than 10% (Jabbari et 
al., 2012; Yaghoubi et al., 2012; Amirnia et al., 2014; 
Eskander and Tewari, 2014).
Cervical cancer is still one of the main problems in 
women health field worldwide. Even with considering 
best available therapies, many patients will die due to 
metastasis or other consequences of cervical cancer 
(Andrae et al., 2012). Relation between human papilloma 
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Abstract
 Background: In cervical cancer patients it has been reported that there in a significant Ki-67/MIB-1 expression 
is correlated with survival in cervical cancer patients. However, the prognostic value is still not well understood. 
Materials and Methods: In the present meta-analysis the prognostic value of Ki-67/MIB-1 with regard to overall 
survival (OS) and disease-free survival (DFS) in cervical cancer was investigated. The databases of PubMed, ISI 
Web of Science, Cochrane Central Register of Controlled Trials, EMBASE, Science Direct and Wiley Online 
Library were used to identify appropriate literature. Results: In order to explore the relationship between Ki-67/
MIB-1 and cervical cancer, we have included 13 studies covering 894 patients in the current meta-analysis. The 
effect of Ki-67/MIB-1 on OS for pooled random effects HR estimate was 1.63 (95%confidence interval (CI) 1.09-
2.45; P<0.05). The pooled HR for DFS was 1.26 (95%CI 0.58-2.73; P>0.05) and the subgroup analysis indicated 
Ki-67/MIB1 was associated with DFS (HR=3.67, 95%CI 2.65-5.09) in Asians. Conclusions: According to this 
meta-analysis, Ki-67/MIB-1 has prognostic value for OS in patients suffering from cervical cancer. For better 
evaluation of the prognostic role of Ki-67/MIB-1 on DFS, studies with larger numbers of patients are needed to 
validate present findings in the future. 
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virus infection and dysplasia and cervical carcinoma has 
been known as a scientific fact (Chaturvedi et al., 2011). 
Human papilloma virus infection in cervical cells’ leads 
to functional changes of host genes and investigating 
these genes can play an important role in screening and 
diagnosing cervical cancer (Ghojazadeh et al., 2012a; 
Ghojazadeh et al., 2012b; Azami-Aghdash et al., 2013; 
Naghavi-Behzad et al., 2013; Sushma et al., 2014). 
These functional changes cause changes in cellular 
cycle which appears through abnormal manifestation of 
proteins related to this cycle, such as Ki-67 (Ikenberg et 
al., 2013; Rostamizadeh et al., 2013; Ghojazadeh et al., 
2014). Ki-67/MIB-1 is known as predictive factor for 
tumor development and its expression is correlated with 
poor prognosis in several types of cancer, such as breast 
cancer and non-small-cell lung carcinoma (Azambuja et 
al., 2007; Azami-Aghdash et al., 2013; Rahimi-Ardabili 
et al., 2012; Fakhrjou et al., 2013; Karami et al., 2013; 
Mohammadzadeh et al., 2013; Aliasgarzadeh et al., 2014; 
Shams-Vahdati et al., 2014). Ki-67 status in different 
tumoral cells and its correlation with prognosis has always 
been a controversial and significant field of research.
In a study investigating Ki-67 levels and prognosis in 
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triple negative breast cancer it had been concluded that, 
high levels of Ki-67 is associated with more aggressive 
clinical features, Also it was suggested that Ki-67 can be 
used as a factor to classify triple negative breast cancer in 
order to recognize prognostic and response characteristics 
(Keam et al., 2011). In another study focusing on 
predicting value of Ki-67 on prognosis in bladder cancer 
it had been concluded that Ki-67 labeling index may be 
a precise predictor for poor prognosis in patients with 
bladder cancer (Sugino et al., 2011). In contrast, according 
to another study it has been reported that the increased 
labeling of Ki-67 was not associated with poor outcomes 
in cervical carcinoma patients of stage I (Van de Putte et 
al., 2004).
Although lymph node status and pathological features 
of primary tumor and FIGO stage are thought to be 
relevant to the prognosis of cervical cancer, considering 
the fact that the clinical value of Ki-67 for prognostication 
of cervical cancer is still doubtful, In this meta-analysis 
it is tried to reveal the impact of Ki-67/MIB-1 on overall 
survival (OS) and/or disease-free survival (DFS) in 
cervical cancer.
Materials and Methods
Selecting publications and inclusion criteria
In this meta-analysis, studies which had investigated 
the association between Ki-67/MIB-1 and prognosis in 
cervical cancer, published during 2000-2014. Libraries 
such as PubMed, ISI Web of Science, EMBASE, Cochrane 
Central Register of Controlled Trials, ScienceDirect and 
Wiley Online Library were searched using the following 
keywords: “cervical cancer”, “cervical neoplasm”, 
“prognosis”, “Ki-67”, “MIB-1”, “proliferation”, 
“survival”. Inclusion criteria for the studies was 
composed of: i) Studies published in English. ii) Studies 
in which patients with cervical cancer are included. 
iii) Studies which has investigated correlation between 
Ki-67expression and the prognosis in cervical cancer. 
iv) Studies with a clear and precise definition of target 
population (clear inclusion and exclusion criteria). v) 
Clearly stated or calculable Hazard ratios (HR) and 95% 
CI for OS or DFS. vi) To avoid duplication, If 2 studies had 
included same samples of patients in several publications, 
the latest study was chosen.
To extend our search range, the reference list of all 
identified studies was inspected. All the titles and abstracts 
of included studies were read by 4 experienced researchers 
to exclude irrelevant ones. Then, full-texts of the studies 
were inspected by researchers to see as if the study is 
included. In case of any disagreements occurred in the 
suitability of studies, the fifth researcher was included 
among researchers, then researchers would conduct a 
discussion until a consensus is finally reached. 
Data extraction
Four authors extracted the required information from 
publications precisely. The following data were collected 
from each study: published year, first author’s name, 
number of patients, antibody detecting Ki-67/MIB-1, 
defined cut-off values, follow-up period, and required 
data to evaluate the relationship between the expression 
of Ki-67/MIB-1 and OS and/or DFS. No minimal number 
of patients was defined to include a study in present meta-
analysis, nor a minimal duration of median follow-up. 
Flow diagram of study is shown in Figure 1. The following 
exclusion criteria were implemented in all studies: i) 
Any research articles but original research articles were 
excluded. ii) Studies with no control group. iii) Articles 
with duplicated data. iv) Articles with no usable data.
Statistical methods
Based on the cut-off points given in the articles by 
the authors, the expression of Ki-67/MIB-1 was divided 
into two groups (negative and positive). The expression 
of Ki-67/MIB-1 on survival was evaluated using HRs 
to quantitatively aggregate the survival rates. After 
calculating or extracting HRs and their 95% confidence 
intervals (CIs) the relationship of prognosis and Ki-67/
MIB-1 expression was inspected. The log-rank statistic 
or its P-value, the HR value estimate and the O-E statistic 
or its variance was used to recover the estimated HR 
value and its variance. Based on the outcome provided 
in the initial publication the HR was evaluated in every 
study. If any of the mentioned parameters could not be 
extracted, the case of patients exposed to the risk in 
each group, the log-rank statistic or the P-value and the 
whole number of the events were searched to calculate 
an approximation of the HRs. Engauge Digitizer software 
was used to extract survival-relative data at stipulated 
time points from figures. The HRs and its standard error 
(SE) were reconstructed with filling spreadsheets with 
HR calculations in order to estimate HRs from published 
summary statistics (Parmar et al., 1998). 
Survival charts were analyzed independently by 4 
people to reduce the inaccuracy. If survival was defined 
for more than two groups (e.g. several cut-off values were 
used to divide the patients into different groups based on 
Ki-67/MIB protein expression), we combined the data 
of some groups in order that we can make a comparison 
between two groups. For each study, the OS and/or DFS 
were analyzed. Considering subgroups such as ethnicity 
(Africans, Europeans or Asians) and various treatments 
(surgery and RT) HR was calcualted. 
All the data analyses were performed with the software 
of STATA 8.2 (StataCorp, College Station, Tex). Using 
the method reported by Yusuf S et al, the individual HRs 
were combined into an overall HR (Yusuf et al., 1985). 
Statistical heterogeneity was measured using the Q 
statistic (p<0.10 was set as representative of significant 
statistical heterogeneity). A random-effects model was 
used if the Q-tests implied that there existed heterogeneity 
between the studies, Also subgroup analysis was used to 
investigate any source of heterogeneity. The publication 
biases was estimated using Begg’s funnel plot. If P value 
was>0.05, it was confirmed that no publication biases 
was found.
Results 
Literature search and characteristics of the included 
studies
Asian Pacific Journal of Cancer Prevention, Vol 16, 2015 6999
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6997
Ki-67/MIB-1 as a Prognostic Marker in Cervical Cancer- a Systematic Review with Meta-Analysis
In present study 13 studies including 894 patients 
were identified, which had been published between 2000 
and 2014 (Ho et al., 2000; Oka et al., 2000; Suzuki et al., 
2000; Graflund et al., 2002; Sultana et al., 2003; Shiohara 
et al., 2005; Bahnassy et al., 2006; Bahnassy et al., 2007; 
Klimek et al., 2011; Zhang et al., 2012a; Zhang et al., 
2012b; Yang et al., 2014). All studies had used indirect 
hemaggultination reaction to detect antibodies. Anti-Ki67 
and MIB-1 were applied to detect the Ki-67 expression. 
Main characteristics of included studies for met-analysis 
of OS and DFS are shown in Table 1 and 2, respectively. 
Subgroup analyses were performed in all 8 studies with 
ethnicity and treatment.
Meta-analysis
The meta-analysis results of OS is shown in Figure 
2. Eleven studies used immunohistochemistry (IHC) 
for OS, the pooled random HR was 1.63 (95%CI 1.09-
2.45; P<0.05), with significant evidence of heterogeneity 
between studies (I2=71.9%, Q=2.36, P<0.05). Restricting 
analysis to ethnicity, data failed to show a correlation in 
Table 1. Main Characteristics of All Studies Included in the Meta-Analysis (Overall Survival)
First Author(publication year) Total Median follow-up Antibody Threshold  Hazard ratio
 patients (months)   (95%CI)
Bahnassy AA (2007) 43 NR MIB-1 1% (PI) 1.53   (1.03-20.7)
Ho DM (2000) 97 83.4 (mean) MIB-1 55% (LI) 3.62   (1.3-10.09)
Klimek M (2011) 122 5y Anti-Ki-67 52% (PI) 2.28   (1.27-4.11)
Oka K (2000) 75 NR Anti-MIB-1 40% (PI) 3.4   (0.53-22.15)
Shiohara SⅠ (2005) 103 65.1 (mean) Anti-Ki-67 50% (PI) 1.57   (0.53-4.66)
Shiohara SⅡ (2005) 103 65.1 (mean) Anti-Ki-67 50% (PI) 1.44   (0.32-6.39)
Sultana H (2003) 30 5y Anti-Ki-67 33% (LI) 0.46   (0.04-5.99)
Suzuki M (2000) 67 78 Anti-MIB-1 26.4% (PI) 0.49   (0.15-2.53)
Yang M (2014) 180 64 (mean) Anti-Ki-67 10% (PI) 3.80   (1.80-4.70)
Zhang T (2012) 40 NR Anti-Ki-67 34.62% (PI) 3.44   (0.7-18.34)
Zhang T (2012) 48 NR Anti-Ki-67 32.74% (PI) 3.04 (0.73-13.26)
CI: confidence interval; NR: not reported; y: years. PI: proliferation index; LI: labeling index
Table 2. Main Features of All Studies Included in the Meta-Analysis (Disease-Free Survival)
First Author Total Median follow-up Antibody Threshold Hazard ratio 
(publication year) patients (months)   (95%CI)
Bahnassy AA(2006) 38 13(mean) NR NR 1.38(0.66-2.87)
Graflund MⅠN+(2002) 37 222(mean) MIB-1 1%(PI) 0.30 (0.10-0.91)
Graflund MⅡN+(2002) 37 222(mean) MIB-1 1%(PI) 0.28(0.01-0.85)
Klimek M(2011) 122 5y Anti-Ki-67 52%(PI) 1.19(1.05-3.50)
Oka K(2000) 75 NR Anti-MIB-1 40%(PI) 4.88(0.42-55.98)
Yang M(2014) 180 64(mean) Anti-Ki-67 10%(PI) 3.80(2.50-4.90)
CI: confidence interval; NR: not reported; y: years; PI: proliferation index
Figure 1. Flow Diagram of Studies Included in the 
Meta-Analysis
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Figure 2. Results of the Meta-Analysis with All 
Evaluable Studies for Overall Survival
Figure 3. Results of the Meta-Analysis With All 
Evaluable Studies For Disease Free Survival
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Africans (HR=1.53, 95%CI 0.34-6.86) and Europeans 
(HR=1.29, 95%CI 0.74-2.23). But statistically difference 
was observed in Asians (HR=1.53, 95%CI 1.04-3.23). 
By treatment subgroup analysis, no dramatic differences 
were discovered in surgery (HR=1.97, 95%CI 0.78-
4.99) or RT treatment (HR=1.56, 95%CI 0.93-2.63). The 
meta-analysis results of DFS is shown in Figure 3. Seven 
studies assessed DFS with the pooled random HR of 1.26 
(95%CI 0.58-2.73; P>0.05) and there was evidence for 
heterogeneity (I2=78.3%, Q=0.59, P>0.05). Altogether, 
six studies were assessed ethnicity. The subgroup analysis 
revealed that Asians was associated with DFS (HR=3.67, 
95%CI 2.65-5.09). Whereas, no association was found 
in Europeans (HR=0.81, 95%CI 0.39-1.67). Of 5 studies 
eligible for treatment subgroup, analysis of these data 
showed that DFS was not positively associated with 
surgery (HR=1.13, 95%CI 0.71-2.24) and RT (HR=1.26, 
95%CI 0.71-2.24). 
To evaluate the meta-results stability sensitivity 
analyses were performed. For OS and DFS, the results 
indicated that random effects estimate before and after 
the deletion studies were similar. Also publication bias 
statistics were determined by using the method of Begg’s 
test. No publication biases were found in 11 OS on studies 
(P=0.907) (Figure 4); But significant difference in 6 
studies on DFS (P=0.014) (Figure 5).
Discussion
As far as Ki-67/MIB-1 is closely integrated with cell 
proliferation, it has been known as a tumor marker in 
cancers due to its close correlation with cell proliferation. 
It has been concluded that Ki-67/MIB-1 expression is 
associated with poor prognosis (Ho et al., 2000; Oka et 
al., 2000; Suzuki et al., 2000; Costa et al., 2001; Sultana 
et al., 2003; Bahnassy et al., 2007; Klimek et al., 2011; 
Zhang et al., 2012a; Zhang et al., 2012b; Yang et al., 2014). 
Based on results of present study Ki-67/MIB-1 can be 
used as a predictor of prognosis because of its profound 
correlation with prognosis.
Detailed cell cycle analysis has revealed that Ki-67/
MIB-1 is present in the nuclei of cells in the G1, S, G2 
and mitosis phases. However, the mechanism for the Ki-67 
gene expression is still unknown. Although some studies 
has revealed possible or partial mechanisms responsible 
for Ki-67/MIB-1 expression; for example in a study it 
was proven that p53-binding motifs intervened part of 
the transcriptional suppression of Ki-67 promoter through 
an interaction with p53 , also p53 was able to suppress 
the Sp1-stimulated Ki-67 promoter activity (Wang et al., 
2011).
There has been many studies investigating the 
relationship between Ki67/MIB-1 expression and 
prognosis in different types of cancers; such as ovarian 
cancer (Battista et al., 2014), breast cancer (Goldhirsch et 
al., 2013), esophageal squamous cell carcinoma (Hu et al., 
2011), lung cancer (Warth et al., 2014), colorectal cancer 
(Peng et al., 2013), glioblastoma (Smith et al., 2012) and 
prostate cancer (Tollefson et al., 2014). All mentioned 
studies indicated that which indicated that Ki-67/MIB-1 
expression was associated with poor prognosis so it can be 
used as a prognostic predictor might be used as a potential 
predictor for the survival of patients with some cancers. 
No biases were found in OS studies, while it was 
shown that there were biases for DFS (Figure 4 and 5). 
The main point which might have affected present meta-
analysis is strict exclusion criteria for this study, for 
example by excluding non-English studies many studies 
bearing prominent results were excluded. 
The techniques used to detect the expression of Ki-67 
/MIB-1 might have been another source of bias. In present 
meta-analysis, not always the antibody used to stain Ki-
67 were the same (Table 1 and 2). It has been shown that 
using equivalent antibodies appeared to make differences 
in variable staining features (Lindboe and Torp, 2002; 
Lindboe et al., 2003). It has been proven that MIB-1 
antibody is the most suitable antibody to detect Ki-67, 
because it has the highest sensitivity and give the clearest 
staining when compared to other available antibodies 
(Fasanella et al., 2011; Lindboe et al., 2003). Also a 
positive ki67 staining of the tumor cells was confirmed 
when it was compare with positive nuclear staining for 
a standard sample. So using different antibodies and a 
protocol to count the stained cells without a confirmed 
standard may lead to a variance in results.
Another potential source of biases, might be due to HR 
variations resulted from extrapolation of survival-relative 
data when no HR existed, using Kaplan-Meier model. 
Although for certain articles HR was directly extracted 
using the original data provided in study. Considering this 
Figure 4. Begg Test was Performed with Pseudo 95% 
Confidence Limits to Detect the Publication Bias Risk 
of Overall Survival (P=0.907)
Figure 5. Begg Test was Performed with Pseudo 95% 
Confidence Limits to Detect the Publication Bias Risk 
of DFS (P=0.014)
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as a potential source of bias, four independent persons 
analyzed the data extracted from Kaplan-Meier model, 
then extrapolated the HR to reduce variability. Then 
estimated HR were compared with the original results, 
but no variances were found.
In present meta-analysis, different cut-off points 
were used to apply it in definition of cervical cancer 
with a positive Ki-67/MIB-1. It is difficult to determine 
a standard critical cut-off values in clinical practice, 
because sometimes median or arbitrary cut-off value 
are selected. It has been already confirmed that using 
minimum P-value approach to select cut-off value may 
result in significant biases in conclusions (Altman et 
al., 1994). Ki67 labelling indices tend to cluster around 
values ending with 5 or 0 both in cases where the values 
were acquired by counting the fraction of stained tumor 
cell nuclei by estimation (Cserni et al., 2014). Although 
it seems more standard for analysis of prognostic markers 
to define the expression levels based on median, but it 
might lead to loss of information (Altman et al., 1994). 
In a study investigating role of Ki-67 proliferative index 
in predicting overall short-term survival in patients with 
typical and atypical pulmonary carcinoid tumors it was 
concluded that Ki67 index cut-off value of 5% can perform 
best for predicting overall survival while satisfying both 
specificity and sensitivity (Walts et al., 2012). In another 
study about breast cancer (Spyratos et al., 2002) using 
different Ki-67/MIB-1 cut-offs, it was concluded that 
a Ki-67/MIB-1 cut-off of 10% was optimal to classify 
tumor (high and low proliferation indexes) in therapeutic 
trials. Also a Ki-67/MIB-1 cut-off of 25% was optimal to 
detect highly proliferative tumors (Spyratos et al., 2002). 
In summary, a suitable threshold is still needed for Ki-67/
MIB-1 to certify for cervical cancer.
Except Ki-67/MIB-1 positivity status, other features 
of disease may influence the survival; such as tumoral cell 
grade, metastasis, lymph node involvement. Unfortunately 
in present study just the univariate prognostic value of 
Ki-67/MIB-1 was investigated. So it is really difficult to 
jump to conclusions before considering other factors. In 
order to overcome this limitation prospective studies with 
larger population are needed.
In conclusion, Ki-67/MIB1 is considered as a 
prognostic marker in cervical cancer. According to the 
results that patients with high Ki-67/MIB1 expression had 
significantly less OS than patients with low expression 
of Ki-67/MIB1 (P<0.001). Although considering 
possible sources of biases it is necessary that studies 
with programmed design to overcome biases needs to 
be conducted, to offer a better conclusion about the 
relationship between Ki-67/MIB1 and prognosis of 
patients with cervical cancer. 
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